{"id":32703,"date":"2025-07-30T08:45:19","date_gmt":"2025-07-30T08:45:19","guid":{"rendered":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/"},"modified":"2025-07-30T08:45:19","modified_gmt":"2025-07-30T08:45:19","slug":"estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un","status":"publish","type":"post","link":"https:\/\/ibima.eu\/es\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/","title":{"rendered":"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n"},"content":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; IV &#8211; PFIZER INC.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; IV &#8211; PFIZER INC.<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[2263,2683],"tags":[],"class_list":["post-32703","post","type-post","status-publish","format-standard","hentry","category-ensayos-clinicos","category-ensayos-clinicos-b-22"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n - Ibima<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/es\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n - Ibima\" \/>\n<meta property=\"og:description\" content=\"MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; IV &#8211; PFIZER INC.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/es\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-30T08:45:19+00:00\" \/>\n<meta name=\"author\" content=\"prodriguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"prodriguez\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/\"},\"author\":{\"name\":\"prodriguez\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"headline\":\"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n\",\"datePublished\":\"2025-07-30T08:45:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/\"},\"wordCount\":63,\"commentCount\":0,\"articleSection\":[\"Ensayos Cl\u00ednicos\",\"Ensayos Cl\u00ednicos - B-22\"],\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/\",\"name\":\"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T08:45:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#\\\/schema\\\/person\\\/40b410344dd5ad2315bb651e3fbfa635\",\"name\":\"prodriguez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g\",\"caption\":\"prodriguez\"},\"sameAs\":[\"https:\\\/\\\/ibima.eu\"],\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/author\\\/prodriguez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n - Ibima","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/es\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/","og_locale":"es_ES","og_type":"article","og_title":"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n - Ibima","og_description":"MANUEL COBO DOLS &#8211; ENSAYO CLINICO COMERCIAL &#8211; IV &#8211; PFIZER INC.","og_url":"https:\/\/ibima.eu\/es\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/","og_site_name":"Ibima","article_published_time":"2025-07-30T08:45:19+00:00","author":"prodriguez","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"prodriguez"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/#article","isPartOf":{"@id":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/"},"author":{"name":"prodriguez","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"headline":"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n","datePublished":"2025-07-30T08:45:19+00:00","mainEntityOfPage":{"@id":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/"},"wordCount":63,"commentCount":0,"articleSection":["Ensayos Cl\u00ednicos","Ensayos Cl\u00ednicos - B-22"],"inLanguage":"es","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/","url":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/","name":"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T08:45:19+00:00","author":{"@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635"},"breadcrumb":{"@id":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/estudio-de-un-solo-grupo-de-lorlatinib-en-participantes-con-cancer-de-pulmon-no-microcitico-cpnm-positivo-para-cinasa-del-linfoma-anaplasico-alk-cuya-enfermedad-ha-progresado-despues-de-recibir-un\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Estudio de un solo grupo de lorlatinib en participantes con c\u00e1ncer de pulm\u00f3n no microc\u00edtico (CPNM) positivo para cinasa del linfoma anapl\u00e1sico (ALK) cuya enfermedad ha progresado despu\u00e9s de recibir un tratamiento previo con un inhibidor de la tirosina cinasa (ITC) ALK de segunda generaci\u00f3n"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/ibima.eu\/es\/#\/schema\/person\/40b410344dd5ad2315bb651e3fbfa635","name":"prodriguez","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3e682b55f425f54644efd95284b890bfd6e129cc61dd791a9d4345ce1ed26791?s=96&d=mm&r=g","caption":"prodriguez"},"sameAs":["https:\/\/ibima.eu"],"url":"https:\/\/ibima.eu\/es\/author\/prodriguez\/"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32703","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/comments?post=32703"}],"version-history":[{"count":3,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32703\/revisions"}],"predecessor-version":[{"id":55762,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/posts\/32703\/revisions\/55762"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/media?parent=32703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/categories?post=32703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibima.eu\/es\/wp-json\/wp\/v2\/tags?post=32703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}